Kura Oncology (NASDAQ:KURA) Posts Quarterly Earnings Results, Misses Estimates By $0.50 EPS

Kura Oncology (NASDAQ:KURA) announced its quarterly earnings results on Thursday. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.50), FiscalAI reports. The business had revenue of $17.34 million for the quarter, compared to analyst estimates of $34.71 million. Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.

Here are the key takeaways from Kura Oncology’s conference call:

• Komzifti launched after FDA approval and generated $2.1M in late‑2025 revenue, with rapid uptake: ~84% of private payers established coverage within 90 days, a two‑day average prescription‑to‑payer decision via KuraConnect, and some payers implementing step edits that require Komzifti before a competitor.
• Komzifti is listed in the FDA Orange Book with patent protection through July 2044, which the company says strengthens the long‑term value of the franchise as it expands into frontline and combination settings.
• Kura is executing an extensive development plan—pivotal KOMET‑017 (two independently powered frontline trials), multiple combination programs (venetoclax, FLT3 inhibitors), and solid‑tumor efforts including darlifarnib—with multiple data readouts planned in 2026 and a phase‑3 top‑line readout expected in 2028.
• Commercial launch and expanded development increased costs: Q4 2025 net loss widened to $81M (vs. $19.2M a year earlier), with higher R&D ($64.4M) and SG&A ($39.1M) contributing to the loss.
• Kura ended 2025 with $667.2M in cash and short‑term investments and expects collaboration revenue and ~<$180M in anticipated milestones to fund its ziftomenib AML program through the first KOMET‑017 phase‑3 results in 2028.

Kura Oncology Stock Performance

Shares of NASDAQ KURA traded down $0.31 during trading hours on Thursday, hitting $8.24. 1,463,609 shares of the company’s stock were exchanged, compared to its average volume of 1,439,818. The company’s 50-day moving average price is $8.84 and its 200-day moving average price is $9.39. Kura Oncology has a 1-year low of $5.41 and a 1-year high of $12.49. The stock has a market capitalization of $717.03 million, a price-to-earnings ratio of -3.32 and a beta of 0.22. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.12 and a quick ratio of 5.12.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 8,180 shares of Kura Oncology stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $69,202.80. Following the sale, the insider directly owned 267,274 shares of the company’s stock, valued at $2,261,138.04. This trade represents a 2.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Francis Burrows sold 23,726 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of $9.78, for a total value of $232,040.28. Following the sale, the insider owned 33,735 shares in the company, valued at approximately $329,928.30. This represents a 41.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 59,794 shares of company stock valued at $537,176 in the last ninety days. Company insiders own 6.40% of the company’s stock.

Institutional Trading of Kura Oncology

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KURA. Virtu Financial LLC bought a new position in Kura Oncology during the fourth quarter worth about $349,000. Invesco Ltd. raised its holdings in shares of Kura Oncology by 14.6% in the 4th quarter. Invesco Ltd. now owns 209,370 shares of the company’s stock worth $2,175,000 after buying an additional 26,683 shares in the last quarter. Mercer Global Advisors Inc. ADV raised its holdings in shares of Kura Oncology by 52.3% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 50,080 shares of the company’s stock worth $520,000 after buying an additional 17,197 shares in the last quarter. Voloridge Investment Management LLC bought a new position in shares of Kura Oncology during the 4th quarter worth approximately $2,505,000. Finally, Virtus Investment Advisers LLC boosted its stake in Kura Oncology by 291.4% in the 4th quarter. Virtus Investment Advisers LLC now owns 66,870 shares of the company’s stock valued at $695,000 after buying an additional 49,785 shares in the last quarter.

Analysts Set New Price Targets

Several research analysts have recently issued reports on KURA shares. Zacks Research upgraded shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. Leerink Partners set a $20.00 price target on Kura Oncology and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. Wall Street Zen downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Monday. UBS Group increased their price target on shares of Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, November 14th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research report on Thursday, January 22nd. Nine research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus price target of $28.00.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.